First Hospitals in the World Achieve Inter-System Connectivity Across Accuray Radiation Therapy Platforms

iDMS™ Data Management System Helps Improve Treatment Outcomes and Efficiency by Sharing Patient Data Throughout the Entire Disease Management Period

SUNNYVALE, Calif., Dec. 14, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Heidelberg University Hospital in Heidelberg, Germany and Oscar Lambret Cancer Center in Lille, France are the first in the world to connect both their Accuray CyberKnife® and TomoTherapy® platforms to the iDMS™ Data Management System. The two facilities are now able to benefit from a centralized database that shares and makes data accessible across the radiation therapy treatment delivery platforms, adding flexibility and improving efficiency in their radiation therapy departments.

The iDMS System allows for the seamless integration of a wide range of technologies including the Radixact™, TomoTherapy and CyberKnife Systems, Accuray Precision™ Treatment Planning System (TPS), and third-party treatment planning and oncology information systems (OIS). As a result, clinicians can leverage the technology and data they need to optimize each patient treatment.

"Heidelberg is an extremely busy hospital, treating more than 4,500 cancer patients per year. We require radiation therapy technology that can keep pace with the demands of our facility and enable us to deliver precise radiation to any tumor in the shortest amount of time possible," said Jürgen Peter Debus, M.D., Ph.D, Medical Director of the Department of Radiation Oncology and Radiation Therapy at Heidelberg University Hospital. "The integration of the Accuray radiation therapy and treatment planning systems with the iDMS System helps us do just that. Treatment planning is now faster, reducing overall treatment time, without sacrificing quality and we can easily transfer patients between systems so we don't risk downtime."

iDMS System Integration BenefitsThe centralized platform for storing and managing all patient and treatment plan data provides the clinical team with numerous benefits including:

  • Seamless treatment of patients on different compatible Accuray delivery systems while maintaining a single treatment record, simplifying and personalizing patient treatment
  • Quick access to previously treated patient files, reducing treatment time
  • Remote review and authorization of treatment plans with PlanTouch™, enhancing flexibility
  • Interfaces with compatible third-party OIS, providing efficient department integration
  • Customizable generation of patient, plan and system reports, supporting practice needs
  • State-of-the-art disaster recovery features, ensuring data integrity

"Radiotherapy is a key component of our multidisciplinary approach to treating cancer. With the installation of the iDMS Data Management System we have the flexibility to treat patients using either our TomoTherapy Systems or our new CyberKnife M6™ System, while maintaining one patient record. This simplifies and speeds up the entire treatment process, while enabling us to adapt how we choose to deliver the radiation treatment at each session based on the needs of the patient," said Xavier Mirabel, M.D., Head of the Department of Radiation Oncology and Brachytherapy, Oscar Lambret Cancer Center.

"One of our main goals in developing the iDMS™ System was to create an exceptional patient treatment delivery experience. The real-world results shared by the Heidelberg and Lille teams demonstrate we are on our way to achieving this goal," said Lionel Hadjadjeba, M.D., Senior Vice President and Chief Commercial Officer at Accuray. "By providing customers with a single point of control for managing multiple, different Accuray radiation therapy platforms, and the seamless connection of systems and data, we are making it easier to provide patients with the best possible treatment at each stage of their cancer treatment journey."

About AccurayAccuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures, and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit

Safe Harbor Statement Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the ability of the iDMS System to improve treatment outcomes, increase efficiencies and reduce treatment time, clinical applications, market acceptance of our new technologies, and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's annual report on Form 10-K, and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Media Contacts:Beth KaplanAccuray                                                                                +1 (408) 789-4426                                                                                                   

Marisa BorgasanoMSLGROUP+1 (781)


View original content with multimedia:
SOURCE Accuray Incorporated